Autor(es): Branco, Susana ; Graça, Maria Inês ; Morais, Sara
Data: 2022
Identificador Persistente: http://hdl.handle.net/10400.21/16171
Origem: Repositório Científico do Instituto Politécnico de Lisboa
Assunto(s): Triple-negative breast cancer; TNBC; Immune checkpoint inhibitors; ICIs; PD-L1; PD-1; CTLA-4; Cancro de mama triplo-negativo; Inibidores de checkpoint imunológico
ABSTRACT - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, associated with a poor prognosis in both early and advanced stages. Chemotherapy remains the standard treatment for these patients, despite its limited benefit. Due to the disease’s aggressive features and lack of targeted therapies, several attempts have been made to disclose novel molecular targets. TNBC is now known to be an immunogenic breast cancer subtype. Therefore, immunotherapy has emerged as a promising treatment option for this disease. During the last few years, immune checkpoint inhibitors (anti-PD1/PD-L1 and anti-CTLA-4 monoclonal antibodies) have been investigated either as monotherapy or combined with conventional therapy in TNBC. Herein, we review the status of immunotherapy in TNBC, focusing on the value of immune checkpoint inhibitors.
